enVista^® & enVista^® toric

Die unternehmenseigene enVista^® IOL Plattform mit dem + für Ihre Patienten

• Glisteningfreies^1,2 Material
• Besondere Widerstandsfähigkeit⁴
• Hervorragende Rotations-und Refraktionsstabilität^1,2,4,5
• Minimierte PCO* Raten^1,6

^{*PCO: Posterior Capsular Opacification}

^{1. Packer et al. Safety and effectiveness of a glistening-free single-piece hydrophobic acrylic intraocular lens (enVista®). Clin Ophthalmol. 2013;7:1905–1912. 2. P. Heiner et al. Safety and effectiveness of a single-piece hydrophobic acrylic intraocular lens (enVista®) – results of a European and Asian-Pacific study. Clin Ophthalmol. 2014;8:629–635. 3. BAUSCH + LOMB data on file: rb_011216_081636_Enhanced enVista_Material Properties Testing 4. Packer et al. Prospective multicenter clinical trial to evaluate the safety and effectiveness of a new glistening-free one-piece acrylic toric intraocular lens. Clin Ophthalmol. 2018;12:1031-103. 5. Garzón N et al. Evaluation of Rotation and Visual Outcomes After Implantation of Monofocal and Multifocal Toric Intraocular Lenses. J. Refract. Surg.2015;31(2), 1-9. 6. Ton Van C, Tran THC. Incidence of posterior capsular opacification requiring Nd:YAG capsulotomy after cataract surgery and implantation of enVista® MX60 IOL. J Fr Ophtalmol. 2018 Dec;41(10):899-903}